Chinese biotech firms need royalty financing as a fallback option
In a season when geopolitical fault lines are quietly redrawing the map of global capital, Royalty Pharma has planted its first Asia-Pacific flag in Hong Kong, arriving precisely as Chinese biotech firms find their traditional funding routes narrowing. The world's largest biopharmaceutical royalty buyer is offering an old instrument — a share of future earnings in exchange for present cash — to a new and urgent audience. It is a reminder that when one door of finance closes, capital does not disappear; it finds a different corridor.
- US investment restrictions and a turbulent Hong Kong IPO market have left Chinese biotech firms scrambling for capital, creating a structural gap that traditional funding can no longer reliably fill.
- The urgency is written in the numbers: Chinese biotech out-licensing deals surged 87% in value through May, signaling that companies are moving fast and accepting larger, more complex arrangements to secure liquidity.
- Royalty Pharma opened a Central Hong Kong office in May, hiring a former Morgan Stanley veteran to lead Asia operations and positioning itself as the go-to alternative financier for drug developers caught between geopolitical pressures.
- A wave of multinational pharmaceutical companies is converging on Hong Kong for the same reasons, turning the city into an unlikely bridge between Western capital markets and mainland Chinese innovation.
- Royalty financing — which avoids equity dilution and debt servicing — aligns investor and developer around a shared outcome, making it a structurally attractive option for firms with strong pipelines but uncertain profitability timelines.
Royalty Pharma, the world's largest buyer of biopharmaceutical royalties, opened its first Asia-Pacific office in Hong Kong in May — a deliberate move timed to meet a surge in financing demand from mainland Chinese drug developers. The company's model is built on a simple exchange: upfront capital now, in return for a percentage of future drug sales. Founded in New York in 1996, it has long operated on this premise globally. Now, with a new office at IFC in Central, it is wagering that Chinese biotech firms will increasingly need exactly this kind of arrangement.
The need is real and growing. US investment restrictions have introduced uncertainty for Chinese companies that once leaned on American venture capital and strategic partnerships. Meanwhile, Hong Kong's IPO market has grown volatile, making public listings a riskier bet for cash-constrained firms. The numbers reflect the pressure: through May, Chinese biotech out-licensing deals rose 30% year over year in volume, while total deal value surged 87% — a gap suggesting that larger, more consequential transactions are accelerating, according to an HSBC report released in late June.
Kenneth Sun, who spent over a decade at Morgan Stanley before joining Royalty Pharma as head of Asia, frames the moment plainly: royalty financing is becoming a necessary fallback, not a niche option. The model's appeal lies in its structure — unlike equity, it does not dilute ownership; unlike debt, it does not demand cash flow to service. Both sides win when the drug succeeds, making it well suited to companies with promising therapies but uncertain roads to profitability.
Royalty Pharma is not arriving alone. A string of multinational pharmaceutical firms have recently set up in Hong Kong, drawn by the city's regulatory clarity and its role as a conduit between Western markets and Chinese innovation. What remains uncertain is whether royalty financing can scale fast enough to meet the capital hunger of a sector that grew up on abundant venture funding — but Royalty Pharma's presence is a clear bet that it can.
Royalty Pharma, the world's largest buyer of biopharmaceutical royalties, opened its first Asia-Pacific office in Hong Kong in May, positioning itself to capture a surge in financing deals from mainland Chinese drug developers. The move reflects a broader shift in how biotech companies are raising capital as traditional funding channels tighten and geopolitical pressures reshape investment flows.
The company's model is straightforward: it provides upfront cash to drug developers and research institutions in exchange for a percentage of future drug sales. Founded in New York in 1996, Royalty Pharma has built a global business on this premise. Now, with its new Central office at IFC, it is betting that Chinese biotech firms will increasingly turn to this form of financing as alternatives dry up.
The timing is deliberate. Kenneth Sun, who spent over a decade at Morgan Stanley before joining Royalty Pharma as senior vice-president and head of Asia, frames the opportunity plainly: Chinese biotech firms need royalty financing as a fallback option. That need is becoming urgent. US investment restrictions on Chinese technology and biotech sectors have created uncertainty for companies that once relied on American venture capital and strategic partnerships. At the same time, Hong Kong's initial public offering market has grown volatile, making it a riskier path for cash-strapped firms seeking to go public.
The numbers tell the story. Through May 31, the total number of Chinese biotech business development deals—including out-licensing agreements, where companies sell rights to their drugs to larger partners—rose 30 percent year over year. More striking: the total value of those deals surged 87 percent over the same period, according to an HSBC report released in late June. That gap between deal count and deal value suggests that larger, more complex transactions are happening, and that companies are moving faster to secure capital.
Royalty Pharma is not alone in recognizing the opportunity. A string of multinational pharmaceutical corporations have recently established offices in Hong Kong, drawn by the same forces: a thriving biotech sector, regulatory clarity, and access to mainland Chinese innovation. The city has become a natural hub for companies seeking to bridge Western capital markets and Chinese drug development.
The broader context matters. Global investors remain interested in Chinese drug breakthroughs despite US pressure. Biotech innovation in China has matured significantly over the past decade, and many companies have developed promising therapies in oncology, immunology, and other fields. But the capital environment has shifted. Money that once flowed freely from American sources now faces regulatory scrutiny. Simultaneously, the rise of artificial intelligence stocks has pulled liquidity away from traditional biotech funding, leaving the sector exposed to market swings.
For Chinese biotech firms, royalty financing offers a lifeline. Unlike equity investment, which dilutes ownership, or debt, which requires cash flow to service, royalties align the interests of financier and developer: both benefit when the drug succeeds. It is a model that works particularly well for companies with promising assets but uncertain paths to profitability—exactly the position many Chinese biotech firms find themselves in.
What remains to be seen is how quickly this alternative funding channel will scale, and whether it will prove sufficient to meet the capital needs of a sector that has grown accustomed to abundant venture funding. Royalty Pharma's Hong Kong office is a bet that it will.
Citações Notáveis
Chinese biotech firms would need royalty financing as an alternative— Kenneth Sun, senior vice-president and head of Asia, Royalty Pharma
A Conversa do Hearth Outra perspectiva sobre a história
Why does a company like Royalty Pharma need a physical office in Hong Kong right now? Couldn't they do this from New York?
Geography matters in biotech. You need to be where the deal-makers are, where you can build relationships with Chinese biotech executives and their advisors. Hong Kong is the bridge—it's where Western capital meets Chinese innovation, and it's where the lawyers and bankers who structure these deals are based.
But the real question is: why are Chinese biotech firms suddenly so interested in royalty financing?
Because their traditional funding sources are drying up. US venture capital is increasingly restricted from investing in Chinese biotech due to geopolitical concerns. Hong Kong's IPO market is volatile. Royalty financing doesn't require giving up equity or taking on debt—it's a way to get cash now in exchange for a piece of future sales.
That sounds like it could be expensive for the biotech company. If a drug sells for a billion dollars, and Royalty Pharma owns 5 percent of that, that's a huge ongoing cost.
It is expensive, but only if the drug succeeds. And that's the point—it's a bet both sides are making. The biotech firm gets cash today when they need it most. Royalty Pharma only makes money if the drug actually works and sells. It's not like debt, where you owe money regardless.
The numbers in the article are striking—87 percent surge in deal value. Is that sustainable?
That's the question everyone is asking. It could reflect genuine momentum in Chinese biotech innovation, or it could be a rush to secure funding before the window closes. The fact that deal count only rose 30 percent while value rose 87 percent suggests bigger, more complex deals are happening. That's probably sustainable. Smaller, speculative deals might not be.
What happens if US restrictions on Chinese biotech get even tighter?
Then royalty financing becomes even more critical. It's one of the few ways Chinese biotech can access Western capital without triggering regulatory concerns. That could make Royalty Pharma's Hong Kong office very valuable very quickly.